These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21282442)

  • 1. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.
    Wiskirchen DE; Koomanachai P; Nicasio AM; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1420-7. PubMed ID: 21282442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
    Bulik CC; Christensen H; Li P; Sutherland CA; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2010 Feb; 54(2):804-10. PubMed ID: 19995927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model.
    Michail G; Labrou M; Pitiriga V; Manousaka S; Sakellaridis N; Tsakris A; Pournaras S
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6028-33. PubMed ID: 24060874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.
    Lim TP; Cai Y; Hong Y; Chan EC; Suranthran S; Teo JQ; Lee WH; Tan TY; Hsu LY; Koh TH; Tan TT; Kwa AL
    Antimicrob Agents Chemother; 2015 May; 59(5):2515-24. PubMed ID: 25691628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae.
    Diep JK; Jacobs DM; Sharma R; Covelli J; Bowers DR; Russo TA; Rao GG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?
    Del Bono V; Giacobbe DR; Marchese A; Parisini A; Fucile C; Coppo E; Marini V; Arena A; Molin A; Martelli A; Gratarola A; Viscoli C; Pelosi P; Mattioli F
    Virulence; 2017 Jan; 8(1):66-73. PubMed ID: 27430122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.
    Tängdén T; Hickman RA; Forsberg P; Lagerbäck P; Giske CG; Cars O
    Antimicrob Agents Chemother; 2014; 58(3):1757-62. PubMed ID: 24395223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae.
    Gaibani P; Lombardo D; Bartoletti M; Ambretti S; Campoli C; Giannella M; Tedeschi S; Conti M; Mancini R; Landini MP; Re MC; Viale P; Lewis RE
    Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1925-1931. PubMed ID: 31278562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
    Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
    J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple combination of meropenem, colistin and tigecycline was bactericidal in a dynamic model despite mere additive interactions in chequerboard assays against carbapenemase-producing Klebsiella pneumoniae isolates.
    Tsala M; Vourli S; Georgiou PC; Pournaras S; Daikos GRL; Mouton JW; Meletiadis J
    J Antimicrob Chemother; 2019 Feb; 74(2):387-394. PubMed ID: 30376071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tigecycline alone or in combination for experimental infections by KPC carbapenemase-producing Klebsiella pneumoniae.
    Fergadaki S; Renieris G; Machairas N; Sabracos L; Droggiti DI; Misiakos E; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2021 Sep; 58(3):106384. PubMed ID: 34161789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
    Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
    Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest.
    Lat A; Clock SA; Wu F; Whittier S; Della-Latta P; Fauntleroy K; Jenkins SG; Saiman L; Kubin CJ
    J Clin Microbiol; 2011 May; 49(5):1795-8. PubMed ID: 21367993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colistin-sparing regimens against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates: Combination of tigecycline or doxycycline and gentamicin or amikacin.
    Tang HJ; Lai CC; Chen CC; Zhang CC; Weng TC; Chiu YH; Toh HS; Chiang SR; Yu WL; Ko WC; Chuang YC
    J Microbiol Immunol Infect; 2019 Apr; 52(2):273-281. PubMed ID: 27133391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of polymyxin B plus imipenem, meropenem, or tigecycline against KPC-2-producing Enterobacteriaceae with high MICs for these antimicrobials.
    Barth N; Ribeiro VB; Zavascki AP
    Antimicrob Agents Chemother; 2015; 59(6):3596-7. PubMed ID: 25801560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae.
    Albiero J; Sy SK; Mazucheli J; Caparroz-Assef SM; Costa BB; Alves JL; Gales AC; Tognim MC
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4128-39. PubMed ID: 27139468
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Huang D; Yu B; Diep JK; Sharma R; Dudley M; Monteiro J; Kaye KS; Pogue JM; Abboud CS; Rao GG
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.